AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02954900 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BNAV
Description: Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
Study NCT02520180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firehawk™ stent system
Description: MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
Study NCT02520180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Xience family Everolimus-Eluting Stent
Description: Abbott Xience family Everolimus-Eluting Stent
Study NCT01927731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Olamine
Description: Given PO
Study NCT01927731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00974519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng 3
Description: Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT00974519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng 1
Description: Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT00974519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study NCT02543021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual chromoendoscopy
Description: Digital / virtual chromoendoscopy with FICE
Study NCT02543021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chromoendoscopy
Description: Conventional chromoendoscopy with indigo carmine dye spray
Study NCT02861391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 AcuPulse Laser
Description: Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
Study NCT02861391 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser
Description: Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
Study NCT00886262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
Study NCT00886262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
Study NCT01567566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise rehabilitation program
Description: 6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
Study NCT01791946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Binocular Treatment
Description: The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
Study NCT01282749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SisterTalk Hartford
Description: 12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
Study NCT01282749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention control video series
Description: Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
Study NCT04108975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle reapproximation during CS
Description: Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
Study NCT01791946 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Binocular Treatment
Description: The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
Study NCT01668524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATS907
Description: Single dose of each of three increasing concentrations
Study NCT01146574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
Study NCT04428242 — intervention group
Intervention type: DEVICE
Intervention: RHMS-RTM
Description: Assessment of retinal thickness.
Study NCT01146574 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01141335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polypropylene mesh
Description: A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
Study NCT01141335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinit® PTFE mesh (WL Gore)
Description: A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
Study NCT04428242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SD-OCT
Description: Assessment of retinal structure.
Study NCT04030962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-242428
Description: Ophthalmic solution administered as a topical eye drop
Study NCT04030962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-231868
Description: Ophthalmic solution administered as a topical eye drop
Study NCT04030962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AGN-242428 Vehicle
Description: Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
Study NCT04030962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGN-242428 Vehicle
Description: Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
Study NCT04030962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AGN-231868 Vehicle
Description: Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
Study NCT04030962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGN-231868 Vehicle
Description: Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
Study NCT04030962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast
Description: Ophthalmic solution administered as a topical eye drop
Study NCT03186534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2GETHER
Description: Communication skills, coping skills, problem-solving, acceptance, HIV prevention
Study NCT03186534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Affect Enhancement
Description: coping skills for enhancing positive emotions, mindfulness
Study NCT01362244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 750 mg of mepolizumab by IV infusion
Study NCT01362244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo by IV infusion
Study NCT01362244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Run In Medication
Description: subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
Study NCT02571439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical TAP block
Description: surgeon administered TAP block
Study NCT02571439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TAP block
Description: Anesthesiologist administered TAP block
Study NCT01014897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS and sham will be applied in random order during standardized occupational therapy
Study NCT04002999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed ceramic bracket and tray
Description: The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, \[24\] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
Study NCT04002999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stock ceramic bracket + 3D printed tray
Description: Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
Study NCT04002999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stock bracket, no tray
Description: Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
Study NCT01984489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01984489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR117887
Study NCT02026817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201 750/10mg
Description: 750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Study NCT02026817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR 750mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Study NCT02026817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10mg
Description: Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Study NCT02571439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% ropivacaine
Description: 20ml of 0.5% ropivacaine is used to perform the TAP block
Study NCT02571439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: 20ml of 0.5% ropivacaine is used to perform the TAP block
Study NCT04598737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra-translucent multilayer zirconia
Description: Ultra-translucent multilayer zirconia laminate veneer treatment
Study NCT04598737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lithium disilicate
Description: Lithium disilicate laminate veneer treatment
Study NCT03056859 — intervention group
Intervention type: DEVICE
Intervention: Extravascular blood pressure transducer
Description: Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
Study NCT01046461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron, Aprepitant, Dexamethasone
Description: Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning
Study NCT02228473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Glycopyrrolate will be administered.
Study NCT02228473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine will be administered.
Study NCT03713814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing.
Study NCT02649387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02649387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01824914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath Videolaryngoscope
Description: A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
Study NCT03001713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CV WIZARD
Description: This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations.
Study NCT01609530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Nitrogen Cryotherapy
Description: Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
Study NCT01609530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed 1064nm Nd:YAG
Description: Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
Study NCT02992522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02992522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT02992522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01342029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks
Study NCT01342029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500-1,000 mg po bid for 2 weeks
Study NCT00224523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Study NCT00224523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Study NCT03629990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Bias Modification (ABM)
Description: Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
Study NCT03629990 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham ABM
Description: Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention.
Study NCT03629990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial therapy for cannabis use disorder.
Description: All participants will receive psychosocial therapy for cannabis use disorder.
Study NCT03629990 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychosocial therapy for cannabis use disorder.
Description: All participants will receive psychosocial therapy for cannabis use disorder.
Study NCT02066532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02066532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
Study NCT04221061 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FluorThanatrace
Description: 18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.
Study NCT02040090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active rabies vaccine (US-FDA approved)
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Study NCT02040090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active rabies vaccine (US-FDA approved)
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Study NCT03656731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast cancer exercise intervention
Description: The exercise-based intervention is comprised of:~1. Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~2. Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~3. Serving of a protein supplement (protein drink or bar) after each supervised training session.
Study NCT03135457 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous RBC transfusion
Description: Autologous RBC transfusion 300ml 10 ml/min
Study NCT03135457 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline transfusion
Description: Saline transfusion 300ml 10ml/min
Study NCT01265823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
Study NCT03714022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants will receive abatacept at a single dose 750 mg as IV infusion.
Study NCT03714022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Participants will receive abatacept at a single dose 750 mg as IV infusion.
Study NCT00715741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water
Description: FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
Study NCT00715741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 0.3 without PEEP
Description: FiO2 0.3 without PEEP